Brokerage firm Barclays Downgrades its rating on CREDIT SUISSE GROUP SPONS ADR(NYSE:CS). The shares have been rated Equal-weight. Previously, the analysts had a Overweight rating on the shares. The rating by Barclays was issued on Jun 9, 2016.
In a different note, On May 19, 2016, UBS said it Upgrades its rating on CREDIT SUISSE GROUP SPONS ADR. The shares have been rated ‘Buy’ by the firm.
CREDIT SUISSE GROUP SPONS ADR (CS) made into the market gainers list on Wednesdays trading session with the shares advancing 1.02% or 0.12 points. Due to strong positive momentum, the stock ended at $11.92, which is also near the day’s high of $12.19. The stock began the session at $12.05 and the volume stood at 52,31,118 shares. The 52-week high of the shares is $29.991 and the 52 week low is $11.7. The company has a current market capitalization of $23,202 M and it has 1,94,64,39,400 shares in outstanding.
CREDIT SUISSE GROUP SPONS ADR(CS) last announced its earnings results on May 10, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $4.89B. Analysts had an estimated revenue of $24.37B. Earnings per share were $-0.16.
Credit Suisse Group AG (Credit Suisse) is a global financial services company. The Company operates in three segments: Private Banking & Wealth Management and Investment Banking. Private Banking & Wealth Management offers advice and a range of financial solutions to private corporate and institutional clients. The Private Banking & Wealth Management comprises the Wealth Management Clients Corporate & Institutional Clients and Asset Management businesses. Asset Management offers a range of investment products and solutions across asset classes and for all investment styles serving governments institutions corporations and individuals across the world. Investment Banking offers investment banking and securities products and services to corporate institutional and government clients around the world. Its products and services include debt and equity underwriting sales and trading M&A advice divestitures corporate sales restructuring and investment research.